SAB Biotherapeutics, Inc.

The company is a clinical-stage biopharmaceutical firm that develops human immunoglobulin G antibodies to treat and prevent immune and autoimmune disorders. It utilizes a specialized production platform involving genetically engineered cattle to generate human polyclonal antibodies without requiring human blood donors. Its primary drug candidate is SAB-142, an immunotherapy designed to protect insulin-producing pancreatic beta cells and slow the progression of type 1 diabetes. The company's therapies are intended for patients suffering from autoimmune conditions, specifically pediatric, adolescent, and adult individuals diagnosed with type 1 diabetes.

Regarding physical operations, the company operates two plasma fractionation and purification suites in Sioux Falls, South Dakota, including a 50-liter scale facility and a 200-liter scale facility. Its clinical activities span multiple international territories, with trial sites distributed across the United States, European Union member nations, the United Kingdom, Australia, and New Zealand.

Summary of the business section of SAB Biotherapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 86 full-time employees, and of these employees, 53 were engaged in research and development activities, 17 were engaged in clinical activities and 16 were engaged in general and administrative activities.”